Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ProBIOPSY: A Multidisciplinary International Consensus on Standards for Prostate Biopsy.

European urology·2026
Same author

Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.

Nature communications·2026
Same author

Germline CDK12 variants in aggressive prostate cancer.

Cancer discovery·2026
Same author

Prognostic Value of Restaging [<sup>18</sup>F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Therapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer.

Future oncology (London, England)·2026
Same author

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes.

Future oncology (London, England)·2026

Related Experiment Video

Updated: Aug 25, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K

Systemic therapy in metastatic hormone-sensitive prostate cancer.

Jodie McDonald1,2, Jonathan O'Brien2,3, Louise Kostos4

  • 1Department of Urology, The Royal Melbourne Hospital.

Current Opinion in Supportive and Palliative Care
|October 14, 2022
PubMed
Summary

Treatment intensification with novel agents and local therapies improves survival in metastatic hormone-sensitive prostate cancer (mHSPC). Tailoring treatment based on disease volume is crucial, though defining volume remains challenging.

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.3K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

14.4K

Related Experiment Videos

Last Updated: Aug 25, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.3K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

14.4K

Area of Science:

  • Oncology
  • Urology

Background:

  • Metastatic hormone-sensitive prostate cancer (mHSPC) treatment has evolved with new data supporting upfront intensification.
  • Recent trials demonstrate survival benefits from combining systemic agents and local therapies.

Approach:

  • Review of landmark trials (ARASENS, PEACE) evaluating treatment intensification strategies.
  • Analysis of data on systemic agents (chemotherapy, androgen receptor pathway inhibitors) and local therapies (primary tumor, metastases).

Key Points:

  • Combination therapy (docetaxel, abiraterone, darolutamide) with androgen deprivation therapy (ADT) shows survival benefit.
  • Local therapy to primary tumor and metastases shows promise for improved survival and recurrence-free survival.
  • Disease volume (high vs. low) is critical for tailoring mHSPC treatment, but definitions are evolving.

Conclusions:

  • Treatment intensification is the new standard of care for mHSPC, supported by robust clinical data.
  • Personalized treatment strategies considering disease volume are essential.
  • Ongoing research and advanced imaging are needed to refine disease volume assessment.